{"disease":{"id":"joint-infection","name":"joint infection"},"drugs":{"marketed":[{"drug_id":"cefoxitin","indication_name":"Bone and joint infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefoxitin-sodium","indication_name":"Bone and joint infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFOXITIN SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":21,"revenue":null,"mechanism":null},{"drug_id":"ceftazidime","indication_name":"Bone and Joint Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"cefuroxime-sodium","indication_name":"Bone and Joint Infections","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"CEFUROXIME SODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"","quality_score":50,"revenue":null,"mechanism":"Cefuroxime inhibits bacterial cell wall synthesis, acting as a bactericidal agent."},{"drug_id":"fusidic-acid","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Synergy for Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"fusidic-acid","indication_name":"Synergy for Staphylococcal Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ramycin","generic_name":"FUSIDIC ACID","company_name":"","drug_phase":"phase_3","molecular_target":"Bile salt export pump","drug_class":"fusidic acid","quality_score":47,"revenue":null,"mechanism":"Fusidic acid works by inhibiting the function of the bacterial ribosome, preventing the production of essential proteins."},{"drug_id":"gentamicin","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin","indication_name":"Synergy for Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin","indication_name":"Synergy for Staphylococcal Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Garamycin","generic_name":"GENTAMICIN","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Transient receptor potential cation channel subfamily V member 5","drug_class":"Aminoglycoside Antibacterial","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"nafcillin-sodium","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nallpen In Plastic Container","generic_name":"NAFCILLIN SODIUM","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":49,"revenue":null,"mechanism":""},{"drug_id":"clindamycin-phosphate","indication_name":"Anaerobic Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cleocin T","generic_name":"CLINDAMYCIN PHOSPHATE","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Lincosamide Antibacterial","quality_score":51,"revenue":null,"mechanism":"Cleocin T works by inhibiting protein synthesis in bacteria, preventing them from producing essential proteins and ultimately leading to cell death."},{"drug_id":"nafcillin","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Nallpen In Plastic Container","generic_name":"NAFCILLIN","company_name":"Pfizer","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"clindamycin","indication_name":"Anaerobic Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cleocin","generic_name":"clindamycin","company_name":"Generic (originally Upjohn/Pfizer)","drug_phase":"marketed","molecular_target":"50S ribosomal protein L10","drug_class":"Lincosamide antibiotic","quality_score":56,"revenue":null,"mechanism":"Lincosamide antibiotic that binds the 50S ribosomal subunit, inhibiting bacterial protein synthesis with excellent anaerobic coverage."},{"drug_id":"metronidazole","indication_name":"Bacteroides Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Metro I.V. In Plastic Container","generic_name":"METRONIDAZOLE","company_name":"Baxter","drug_phase":"marketed","molecular_target":"","drug_class":"Nitroimidazole Antimicrobial [EPC]","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"piperacillin","indication_name":"Bacteroides Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"piperacillin","indication_name":"Enterococcus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"piperacillin","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Pipracil","generic_name":"PIPERACILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"piperacillin","quality_score":10,"revenue":null,"mechanism":"Pipracil works by inhibiting bacterial cell wall synthesis, ultimately leading to cell lysis and death."},{"drug_id":"ciprofloxacine","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacine","indication_name":"Serratia Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ciprofloxacine","company_name":"Poitiers University Hospital","drug_phase":"discontinued","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"","quality_score":null,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Synergy for Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"gentamicin-sulfate","indication_name":"Synergy for Staphylococcal Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Gentamicin","generic_name":"Gentamicin Sulfate","company_name":"Merck & Co.","drug_phase":"marketed","molecular_target":"Dihydrofolate reductase","drug_class":"gentamicin","quality_score":55,"revenue":null,"mechanism":""},{"drug_id":"cefamandole","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefadole","generic_name":"CEFAMANDOLE","company_name":"","drug_phase":"phase_2","molecular_target":"Solute carrier family 15 member 1","drug_class":"cefamandole","quality_score":null,"revenue":null,"mechanism":"Cefadole works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"ceftriaxon","indication_name":"E. Coli Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ceftriaxon","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ceftriaxon","indication_name":"Klebsiella Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ceftriaxon","indication_name":"Proteus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"ceftriaxon","indication_name":"Streptococcal Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftriaxon","company_name":"Centre Hospitalier Universitaire Vaudois","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"","quality_score":19,"revenue":null,"mechanism":null},{"drug_id":"amikacin","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Arikayce Kit","generic_name":"AMIKACIN","company_name":"Bristol-Myers Squibb","drug_phase":"marketed","molecular_target":"","drug_class":"Aminoglycoside Antibacterial","quality_score":10,"revenue":null,"mechanism":"Amikacin works by binding to bacterial ribosomes, inhibiting protein synthesis and ultimately killing the bacteria."},{"drug_id":"ceftazidime","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Klebsiella Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"ceftazidime","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"CEFTAZIDIME","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"","drug_class":"ceftazidime","quality_score":10,"revenue":null,"mechanism":"Fortaz works by binding to penicillin-binding proteins on bacterial cell walls, preventing them from forming a strong cell wall and ultimately leading to bacterial cell death."},{"drug_id":"cefoxitin","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Mefoxin In Sodium Chloride 0.9% In Plastic Container","generic_name":"CEFOXITIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"cefotetan","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cefotan","generic_name":"CEFOTETAN","company_name":"","drug_phase":"marketed","molecular_target":"Prostaglandin G/H synthase 2","drug_class":"Cephalosporin Antibacterial [EPC]","quality_score":60,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"TICARCILLIN","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ticarcillin-disodium","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Ticarcillin","generic_name":"TICARCILLIN DISODIUM","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Penicillin-class Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"cefuroxime","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Zinacef","generic_name":"CEFUROXIME","company_name":"GSK","drug_phase":"marketed","molecular_target":"Carbonic anhydrase 2","drug_class":"Cephalosporin Antibacterial","quality_score":65,"revenue":null,"mechanism":"Zinacef works by inhibiting bacterial cell wall synthesis, ultimately leading to bacterial cell death."},{"drug_id":"clavulanic-acid","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Augmentin 250","generic_name":"CLAVULANIC ACID","company_name":"Dr Reddys Labs Inc","drug_phase":"marketed","molecular_target":"","drug_class":"beta Lactamase Inhibitor","quality_score":35,"revenue":null,"mechanism":""},{"drug_id":"tazicef","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"tazicef","indication_name":"Klebsiella Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"tazicef","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"tazicef","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Fortaz","generic_name":"Ceftazidime","company_name":"Pai Holdings Pharm","drug_phase":"marketed","molecular_target":"Bacterial cell wall","drug_class":"Third-generation cephalosporin","quality_score":10,"revenue":null,"mechanism":"Bactericidal agent inhibiting bacterial cell wall synthesis with beta-lactamase resistance."},{"drug_id":"norfloxacin","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"norfloxacin","indication_name":"Serratia Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Noroxin","generic_name":"NORFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-1","drug_class":"Quinolone Antimicrobial","quality_score":10,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ofloxacin","indication_name":"Serratia Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Floxin","generic_name":"OFLOXACIN","company_name":"","drug_phase":"marketed","molecular_target":"Histamine H3 receptor","drug_class":"Quinolone Antimicrobial [EPC]","quality_score":65,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Bacteroides Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Peptococcus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Peptostreptococcus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Proteus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftizoxime","indication_name":"Streptococcal Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Epocelin","generic_name":"CEFTIZOXIME","company_name":"","drug_phase":"marketed","molecular_target":"","drug_class":"Cephalosporin Antibacterial","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ciprofloxacin","indication_name":"Serratia Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Cipro","generic_name":"ciprofloxacin","company_name":"Bayer AG","drug_phase":"marketed","molecular_target":"DNA topoisomerase II, DNA gyrase subunit A, DNA gyrase subunit A","drug_class":"Fluoroquinolone antibiotic","quality_score":40,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"E. Coli Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"Klebsiella Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"Proteus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"ceftriaxone","indication_name":"Streptococcal Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Rocephin","generic_name":"ceftriaxone","company_name":"Generic (originally Roche)","drug_phase":"marketed","molecular_target":"Alpha-synuclein, D-amino-acid oxidase, Penicillin-binding protein 1A","drug_class":"Cephalosporin antibiotic (third-generation)","quality_score":50,"revenue":null,"mechanism":""},{"drug_id":"oxacillin","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"Bactocill In Plastic Container","generic_name":"OXACILLIN","company_name":"Apothecon","drug_phase":"marketed","molecular_target":"Dual 3',5'-cyclic-AMP and -GMP phosphodiesterase 11A, Prostaglandin G/H synthase 1, Prostaglandin G/H synthase 2","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"Klebsiella Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ceftazidim","indication_name":"Staphylococcus Aureus Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ceftazidim","company_name":"Tel-Aviv Sourasky Medical Center","drug_phase":"marketed","molecular_target":"Penicillin-binding protein 1A, Penicillin-binding protein 1B, Peptidoglycan synthase FtsI","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"metronidazol","indication_name":"Bacteroides Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Metronidazol","company_name":"University of Oslo","drug_phase":"marketed","molecular_target":"Thioredoxin reductase","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"EnterobacterJoint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Pseudomonas Aeruginosa Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null},{"drug_id":"ofloxacine","indication_name":"Serratia Joint Infection","indication_type":"approved","phase":null,"line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":null,"generic_name":"Ofloxacine","company_name":"Assistance Publique - Hôpitaux de Paris","drug_phase":"phase_3","molecular_target":"Gamma-aminobutyric acid receptor subunit alpha-2, Histamine H3 receptor, Muscarinic acetylcholine receptor M1","drug_class":"","quality_score":null,"revenue":null,"mechanism":null}],"pipeline":[],"offLabel":[],"totalMarketed":74,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT05530551","title":"Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With OA","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":20000,"lead_sponsor_name":"Soren Overgaard","has_results":false},{"nct_id":"NCT06418048","title":"INfectious DIsease REgistry BIObank","phase":"","overall_status":"RECRUITING","enrollment_count":10000,"lead_sponsor_name":"IRCCS San Raffaele","has_results":false},{"nct_id":"NCT06771050","title":"Randomised Arthroplasty Infection Worldwide Multidomain Adaptive Platform (ROADMAP) Trial","phase":"PHASE4","overall_status":"NOT_YET_RECRUITING","enrollment_count":2500,"lead_sponsor_name":"University of Newcastle, Australia","has_results":false},{"nct_id":"NCT05530174","title":"Effect of Single vs Multiple Prophylactic Antibiotic Doses on PJI Following Primary THA in Patients With a Fracture","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":2000,"lead_sponsor_name":"Soren Overgaard","has_results":false},{"nct_id":"NCT05117671","title":"Is the EBJIS Definition of Prosthetic Joint Infection Meaningful in Our Clinical Practice?","phase":"","overall_status":"COMPLETED","enrollment_count":1554,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT05399186","title":"Arthroplasty and Modifiable Risk Factors","phase":"NA","overall_status":"COMPLETED","enrollment_count":1484,"lead_sponsor_name":"Landspitali University Hospital","has_results":false},{"nct_id":"NCT04933344","title":"Pharmacokinetics and Toxicodynamics of Daptomycin in Bone and Joint Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":1130,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03335592","title":"Cost of Off-label Antibiotics in Osteoarticular Infections","phase":"","overall_status":"TERMINATED","enrollment_count":1000,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT01957228","title":"Causative Diagnosis on Prosthetic Joint Infections: Establishment of a Comprehensive Diagnostic Strategy","phase":"NA","overall_status":"COMPLETED","enrollment_count":980,"lead_sponsor_name":"Assistance Publique Hopitaux De Marseille","has_results":false},{"nct_id":"NCT05519007","title":"Rate of Total Joint Infection 90-day After Surgery Following Irrigation With Next Science No-Rinse Solution vs SOC Alone","phase":"NA","overall_status":"RECRUITING","enrollment_count":936,"lead_sponsor_name":"Northwell Health","has_results":false},{"nct_id":"NCT06402591","title":"Results of Extended Versus Single Dose Antibiotic Prophylaxis In Orthopedic Revision Arthroplasty in Nijmegen.","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":751,"lead_sponsor_name":"Radboud University Medical Center","has_results":false},{"nct_id":"NCT05341908","title":"Prevalence of Pathogens in Synovial Fluid Obtained From Emergency Department Patients","phase":"","overall_status":"COMPLETED","enrollment_count":750,"lead_sponsor_name":"Olive View-UCLA Education & Research Institute","has_results":false},{"nct_id":"NCT03826108","title":"ARTHR-IS (Arthroplasties' Infections Due to Staphylococcus Aureus)","phase":"","overall_status":"UNKNOWN","enrollment_count":600,"lead_sponsor_name":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","has_results":false},{"nct_id":"NCT03191292","title":"Bacterial Epidemiology and Empirical Antibiotherapy in Patients With Prosthetic Joint Infection","phase":"","overall_status":"COMPLETED","enrollment_count":567,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT03806166","title":"Short or Long Antibiotic Regimes in Orthopaedics","phase":"NA","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Oxford University Hospitals NHS Trust","has_results":false},{"nct_id":"NCT05060952","title":"Calprotectin in Chronic Prosthetic Joint Infection","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"Technical University of Munich","has_results":false},{"nct_id":"NCT05284318","title":"Prospective Cohort Study on Antibiotic Course and Efficacy After Two-stage Revision in PJI.","phase":"","overall_status":"RECRUITING","enrollment_count":500,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT05084378","title":"Evaluation of Emerging New Treatments for Infection Prevention in Total Joint Replacement","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":495,"lead_sponsor_name":"Hamilton Health Sciences Corporation","has_results":false},{"nct_id":"NCT07313215","title":"Rifampin-combined Antibiotic Therapy for Staphylococcal PJI","phase":"NA","overall_status":"RECRUITING","enrollment_count":428,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT04413565","title":"Infection Rate of One-Stage Bilateral TKR - One Surgeon Sequential vs. Two Surgeon Simultaneous: A Randomized Controlled Study","phase":"NA","overall_status":"UNKNOWN","enrollment_count":413,"lead_sponsor_name":"Bezmialem Vakif University","has_results":false},{"nct_id":"NCT04722926","title":"Lyon PJI Retrospective Cohort Study","phase":"","overall_status":"UNKNOWN","enrollment_count":400,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT04418882","title":"Septic Management and Outcome of Open Fracture","phase":"","overall_status":"COMPLETED","enrollment_count":400,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06267287","title":"Microbiological Structure of Pathogens of Periprosthetic Infection of Large Joints in the Post-Covid Period","phase":"","overall_status":"COMPLETED","enrollment_count":342,"lead_sponsor_name":"Federal State Budgetary Organization, Federal Center for Traumatology, Orthopedics and Arthroplasty","has_results":false},{"nct_id":"NCT04723940","title":"Or v IV Antibiotics for Infection","phase":"PHASE3","overall_status":"UNKNOWN","enrollment_count":308,"lead_sponsor_name":"Rothman Institute Orthopaedics","has_results":false},{"nct_id":"NCT03274466","title":"Closed Incision Negative Pressure Therapy Versus Standard of Care Surgical Dressing in Revision Total Knee Arthroplasty","phase":"NA","overall_status":"COMPLETED","enrollment_count":294,"lead_sponsor_name":"KCI USA, Inc","has_results":true},{"nct_id":"NCT04858217","title":"Periprosthetic Joint Infections: Diagnostic Accuracy and Cost-effectiveness Analysis of Serum and Synovial Markers","phase":"","overall_status":"RECRUITING","enrollment_count":270,"lead_sponsor_name":"Istituto Ortopedico Rizzoli","has_results":false},{"nct_id":"NCT06268795","title":"A Diagnostic Test Accuracy Study Comparing Biopsy to Aspiration in Shoulder and Elbow Arthroplasty Revision Surgery (BASE Study)","phase":"","overall_status":"RECRUITING","enrollment_count":244,"lead_sponsor_name":"Wrightington, Wigan and Leigh NHS Foundation Trust","has_results":false},{"nct_id":"NCT04390607","title":"Leukocyte Esterase Sensor Test","phase":"","overall_status":"UNKNOWN","enrollment_count":230,"lead_sponsor_name":"Rothman Institute Orthopaedics","has_results":false},{"nct_id":"NCT05211011","title":"Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":226,"lead_sponsor_name":"Charite University, Berlin, Germany","has_results":false},{"nct_id":"NCT03260010","title":"Efficacy and Safety of Intravenous Fosfomycin in Prosthetic Joint Infection","phase":"PHASE4","overall_status":"UNKNOWN","enrollment_count":224,"lead_sponsor_name":"Pro-Implant Foundation","has_results":false},{"nct_id":"NCT05361941","title":"Multicenter Trial of Antibiotic Eluting Graft for Promoting New Bone Growth In/near Infected Bone Cavities","phase":"NA","overall_status":"RECRUITING","enrollment_count":204,"lead_sponsor_name":"Elute, Inc.","has_results":false},{"nct_id":"NCT07284563","title":"Ultralow Dose PET Imaging for 18F-NaF Uptake","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":200,"lead_sponsor_name":"Akiva Mintz","has_results":false},{"nct_id":"NCT06467734","title":"Prospective Cohort Study of Synovial Biomarkers in the Diagnosis and Prediction of Periprosthetic Joint Infection","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":200,"lead_sponsor_name":"First Affiliated Hospital of Xinjiang Medical University","has_results":false},{"nct_id":"NCT05320354","title":"Diagnosis and Bacterial Identification of Periprosthetic Joint Infection With Microbial-ID","phase":"","overall_status":"UNKNOWN","enrollment_count":200,"lead_sponsor_name":"UMC Utrecht","has_results":false},{"nct_id":"NCT07232771","title":"Reinfection and Re-revision Rates of Periprosthetic Knee Infection Under Four Different Surgical Strategies","phase":"","overall_status":"COMPLETED","enrollment_count":200,"lead_sponsor_name":"First Affiliated Hospital of Fujian Medical University","has_results":false},{"nct_id":"NCT03134521","title":"Population Pharmacokinetic Analysis of Daptomycin in Patients With Osteoarticular Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":189,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06189885","title":"Preoperative Daptomycin Prophylaxis in Two-Stage Exchange Arthroplasty: A Prospective, Randomized, Double-Blinded Trial","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":184,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT04563325","title":"Oral-only Antibiotics for Bone and Joint Infections in Children","phase":"PHASE4","overall_status":"COMPLETED","enrollment_count":180,"lead_sponsor_name":"Rigshospitalet, Denmark","has_results":false},{"nct_id":"NCT03850860","title":"Comparison of Two Empirical Antimicrobial Therapies of Prosthetic Joint Infection","phase":"","overall_status":"COMPLETED","enrollment_count":178,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT05265598","title":"Is This PJI Really Acute: A Quantitative Sonication Fluid Analysis (Sonic)","phase":"","overall_status":"COMPLETED","enrollment_count":176,"lead_sponsor_name":"University Hospital, Basel, Switzerland","has_results":false},{"nct_id":"NCT07494630","title":"Joint Endoprostheses Can Succesfully Treat Disabling Osteoarthritis. However, Infection is an Important Cause of Failure. Adequate Diagnostics Remains Challenging. Combining Advanced Imaging With Next-generation Sequencing of Samples Obtained Endoscopically Should Aid in Mapping and Characterizing.","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":174,"lead_sponsor_name":"University Hospital, Ghent","has_results":false},{"nct_id":"NCT06782295","title":"The Use of CCK vs PS in Revision TKAs","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":170,"lead_sponsor_name":"Rush University Medical Center","has_results":false},{"nct_id":"NCT03694925","title":"Diagnostic Utility of a Novel Point-of-Care Test of Calprotectin for Revision Total Knee Arthroplasty","phase":"","overall_status":"COMPLETED","enrollment_count":156,"lead_sponsor_name":"The Cleveland Clinic","has_results":true},{"nct_id":"NCT06919913","title":"The Effect of Peri-Operative Adjunctive Probiotics on Immunological Markers in Cases of Prosthetic Joint Infection of the Hip and Knee","phase":"NA","overall_status":"RECRUITING","enrollment_count":152,"lead_sponsor_name":"NYU Langone Health","has_results":false},{"nct_id":"NCT04056780","title":"Integrated Microfluidic Systems for Diagnosis of Periprosthetic Joint Infection","phase":"","overall_status":"UNKNOWN","enrollment_count":150,"lead_sponsor_name":"Chang Gung Memorial Hospital","has_results":false},{"nct_id":"NCT06627842","title":"OsteoArticular Sepsis in Intensive Care unitS","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07107685","title":"Prosthetic Joint Infection : Lessons From Deceased Patients in Critical Care.","phase":"","overall_status":"RECRUITING","enrollment_count":150,"lead_sponsor_name":"Assistance Publique - Hôpitaux de Paris","has_results":false},{"nct_id":"NCT07322289","title":"Antibiotic-coated Braided Suture Study","phase":"NA","overall_status":"NOT_YET_RECRUITING","enrollment_count":142,"lead_sponsor_name":"University of Miami","has_results":false},{"nct_id":"NCT04620395","title":"Percutaneous Punch Biopsy for Diagnosis of Septic and Aseptic Prosthetic Joint Failure","phase":"NA","overall_status":"UNKNOWN","enrollment_count":132,"lead_sponsor_name":"Vivantes Netzwerk für Gesundheit GmbH","has_results":false},{"nct_id":"NCT03769337","title":"New Markers for Diagnosis of Prosthetic Infections","phase":"","overall_status":"UNKNOWN","enrollment_count":130,"lead_sponsor_name":"I.R.C.C.S Ospedale Galeazzi-Sant'Ambrogio","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}